Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v7i3.5447
Abstract
The clinical treatment of malignant solid tumors still faces problems such as significant systemic chemotherapy toxicity and side effects, poor local tumor control effects, and limited treatment methods for advanced patients. Transarterial interventional chemotherapy is a minimally invasive local treatment method, which has the advantages of high local drug concentration, minimal systemic adverse reactions, and can be performed multiple times. It has been widely used in many solid tumors.
Keywords
interventional transarterial chemotherapy; anti-tumor; treatment; application
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] MENG W, PAN L, HUANG L, et al. Applications of image-guided locoregional transarterial chemotherapy in patients with inoperable colorectal cancer: a review[J]. Frontiers in Oncology, 2024, 14: 1464242.
[2] SWIERZ M J, STORMAN D, MITUS J W, et al. Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases[J]. Cochrane Database of Systematic Reviews, 2024(8): CD012757.
[3] HE Y, et al. Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death receptor-1 inhibitors for unresectable hepatocellular carcinoma: a systematic review and meta-analysis[J]. Translational Cancer Research, 2025, 14(8): 4976-4988.
[4] ANKER J M, et al. Expanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies[J]. Cancers, 2025, 17(5): 726.
[5] LIU Y, CHANG W, ZHOU B, et al. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial[J]. The British Journal of Surgery, 2021, 108(4): 373-379.
[6] Huang Zhengli, Wang Xiaoyan, Xue Youhua, etc. A review of the scope of symptom group research in liver cancer patients after arterial chemoembolization [J]. Journal of Nursing, 2026, 41 (13) 121-124.
[7] Sun Wan, Song Ziyang, Ma Fei, etc. Animal experimental study on the application of multimodal imaging drug loaded microspheres in transarterial chemoembolization of liver tumors [J/OL]. Journal of Oncology, 1-7 [2026-07-13] https://link.cnki.net/urlid/33.1266.R.20260622.1951.002.
[8] Yang Han, Li Mingjin, Zhao Nian, etc. Risk factors and predictive study of liver abscess in patients with liver cancer after transcatheter arterial chemoembolization [J]. Anhui Medical Journal, 2026, 30 (6) 1209-1214.
[9] Meng Dandan. The efficacy of hepatic artery catheterization chemotherapy infusion combined with hepatic artery chemoembolization in the treatment of advanced liver cancer and liver metastasis patients [J]. Medical Clinical Research, 2026, 43 (5) 746-749.
[10] Zhu Duo, He Li. Clinical efficacy and safety of transarterial chemoembolization combined with hepatic artery infusion chemotherapy in the treatment of giant hepatocellular carcinoma [J]. Chinese Journal of Practical Medicine, 2026, 21 (11) 13-17.
[11] Li Qianqian, Wang Jie, Li Yajie. The effect of evidence-based nursing on nausea and vomiting in patients with advanced liver cancer after transcatheter arterial chemoembolization [J]. Basic and Clinical Oncology, 2026, 39 (1) 117-119.
[2] SWIERZ M J, STORMAN D, MITUS J W, et al. Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases[J]. Cochrane Database of Systematic Reviews, 2024(8): CD012757.
[3] HE Y, et al. Transarterial chemoembolization combined with tyrosine kinase inhibitors and programmed death receptor-1 inhibitors for unresectable hepatocellular carcinoma: a systematic review and meta-analysis[J]. Translational Cancer Research, 2025, 14(8): 4976-4988.
[4] ANKER J M, et al. Expanding the Scope of Interventional Oncology: Locoregional Therapies in Extrahepatic Malignancies[J]. Cancers, 2025, 17(5): 726.
[5] LIU Y, CHANG W, ZHOU B, et al. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial[J]. The British Journal of Surgery, 2021, 108(4): 373-379.
[6] Huang Zhengli, Wang Xiaoyan, Xue Youhua, etc. A review of the scope of symptom group research in liver cancer patients after arterial chemoembolization [J]. Journal of Nursing, 2026, 41 (13) 121-124.
[7] Sun Wan, Song Ziyang, Ma Fei, etc. Animal experimental study on the application of multimodal imaging drug loaded microspheres in transarterial chemoembolization of liver tumors [J/OL]. Journal of Oncology, 1-7 [2026-07-13] https://link.cnki.net/urlid/33.1266.R.20260622.1951.002.
[8] Yang Han, Li Mingjin, Zhao Nian, etc. Risk factors and predictive study of liver abscess in patients with liver cancer after transcatheter arterial chemoembolization [J]. Anhui Medical Journal, 2026, 30 (6) 1209-1214.
[9] Meng Dandan. The efficacy of hepatic artery catheterization chemotherapy infusion combined with hepatic artery chemoembolization in the treatment of advanced liver cancer and liver metastasis patients [J]. Medical Clinical Research, 2026, 43 (5) 746-749.
[10] Zhu Duo, He Li. Clinical efficacy and safety of transarterial chemoembolization combined with hepatic artery infusion chemotherapy in the treatment of giant hepatocellular carcinoma [J]. Chinese Journal of Practical Medicine, 2026, 21 (11) 13-17.
[11] Li Qianqian, Wang Jie, Li Yajie. The effect of evidence-based nursing on nausea and vomiting in patients with advanced liver cancer after transcatheter arterial chemoembolization [J]. Basic and Clinical Oncology, 2026, 39 (1) 117-119.
Copyright © 2026 Ziqian Li
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License